Announcements Trials
Browse Landscape

Phase

Phase 2 32Phase 1 16Phase 1/2 13Phase 3 7Phase 4 3Phase 2/3 2Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

Magnetic Resonance Spectroscopy 26pembrolizumab 17Radiotherapy 17Specimen Handling 16Nivolumab 15Cyclophosphamide 14Temozolomide 11Biopsy 11fludarabine 9Fluorodeoxyglucose F18 9X-Rays 8Etoposide 7Bevacizumab 7Standard of Care 6Radiation 6Paclitaxel 6Dexamethasone 6Cisplatin 6Carboplatin 6Surgical Procedures, Operative 5Ipilimumab 5Doxorubicin 5Aspirin 5venetoclax 4fluciclovine F-18 4atezolizumab 4abemaciclib 4Vincristine 4Rituximab 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × trametinib × 1 year × Clear all
NCT03085056 2025-07-03

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
13 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡